Business Context and Reporting Period
Passage Bio, Inc. filed this Form 8-K on December 27, 2023, under Item 8.01 to disclose a proposed settlement of a stockholder derivative action concerning historical compensation practices for non-employee directors. The report was signed on December 29, 2023.
Financial and Liquidity Information
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
The Company agreed to pay plaintiff’s counsel attorneys’ fees and expenses of up to $390,000, subject to court approval of the settlement.
Material Changes and Unusual Items
- On December 13, 2023, the Company and certain directors entered into a Stipulation and Agreement of Compromise, Settlement and Release with a Company stockholder.
- Subject to court approval, the Company will implement and maintain specified changes to director compensation policies and practices for a designated period.
- The Company will provide additional compensation-related disclosures in its annual proxy statement.
- The proposed settlement includes a release of claims related to the derivative action, without admission of wrongdoing.
- If approved, all claims asserted in the derivative action will be dismissed.
Outlook, Risks, and Contingencies
The settlement remains subject to approval by the Delaware Court of Chancery. The principal financial contingency disclosed is the payment of up to $390,000 in attorneys’ fees and expenses if the settlement is approved. The filing does not provide a clear estimate of any other potential costs or effects on future financial results.
Key Facts to Verify
- Whether the Delaware Court of Chancery approved the proposed settlement.
- The final amount of attorneys’ fees and expenses paid.
- The specific director compensation policy changes and their implementation period.
- The additional compensation disclosures included in the Company’s subsequent annual proxy statement.
- Whether the derivative action was formally dismissed after settlement approval.